Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We explored whether spontaneous imaging tumor growth (estimated by the velocity of diametric expansion) and isocitrate dehydrogenase 1 (IDH1) mutation (estimated by IDH1 immunoexpression) were independent predictors of long-term outcomes of diffuse low-grade gliomas in adults. METHODS: One hundred thirty-one adult patients with newly diagnosed supratentorial diffuse low-grade gliomas were retrospectively studied. RESULTS: Isocitrate dehydrogenase 1 mutations were present in 107 patients. The mean spontaneous velocity of diametric expansion was 5.40 ± 5.46 mm/y. During follow-up (mean, 70 ± 54.7 mo), 56 patients presented a malignant transformation and 23 died. The median malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (149 and 198 mo, respectively) than in cases of fast velocity of diametric expansion (46 and 82 mo; P < .001 and P < .001, respectively) and in cases with IDH1 mutation (100 and 198 mo, respectively) than in cases without IDH1 mutation (72 mo and not reached; P = .028 and P = .001, respectively). In multivariate analyses, spontaneous velocity of diametric expansion and IDH1 mutation were independent prognostic factors for malignant progression-free survival (P < .001; hazard ratio, 4.23; 95% CI, 1.81-9.40 and P = .019; hazard ratio, 2.39; 95% CI, 1.19-4.66, respectively) and for overall survival (P < .001; hazard ratio, 26.3; 95% CI, 5.42-185.2 and P = .007; hazard ratio, 17.89; 95% CI, 2.15-200.1, respectively). CONCLUSIONS: The spontaneous velocity of diametric expansion and IDH1 mutation status are 2 independent prognostic values that should be obtained at the beginning of the management of diffuse low-grade gliomas in adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VDE, the rate of change in tumor diameter over time, is an independent predictor of outcome in LGGs [43,44,45].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [43]
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008 · cited 1×
“status has been shown to correlate independently with overall survival in gliomas whatever their histopathological grade.(8,9,15) The spontaneous VDE has been shown to correlate independently with malignant progression-free survival and with overall survival.”
BackgroundPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505 · cited 2×
“These tumors grow continuously and progress to a higher grade of malignancy, leading to neurological disability and death.(2) Several risk factors allow prognostic refinements for LGGs: clinical parameters (age, preoperative neurological deficit, increased intracranial pressure, seizures), neuroimaging findings (tumor…”
BackgroundSelf-citationContinuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493
Self-citationMetellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260 · cited 2×
“IDH1 mutation and 1p19q codeletion are independent favorable prognostic factors for LGGs, but previous studies showed that these molecular parameters are closely associated.(15,17) Moreover, 1p19q codeletion status affects the imaging tumor growth, although IDH1 mutation does not.”
BackgroundPallud, J., Mandonnet, E., Duffau, H., Kujas, M., Guillevin, R., Galanaud, D., Taillandier, L., & Capelle, L. (2006) · Annals of Neurology · doi:10.1002/ana.20946 · Cited by 250 · cited 5×
“Although spontaneous VDE was shown to correlate with molecular markers, it represents an independent prognostic parameter for overall survival and for malignant progression-free survival and may help in predicting the natural history of LGGs.11,12 As the spontaneous VDE adds to IDH1 mutation status and to 1p19q codele…”
BackgroundSelf-citationChang, E. F., Smith, J. S., Chang, S. M., Lamborn, K. R., Prados, M. D., Butowski, N., Barbaro, N. M., Parsa, A. T., Berger, M. S., & Mcdermott, M. M. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/109/11/0817 · Cited by 234
Dynamic history of low‐grade gliomas before and after temozolomide treatment
Ricard, D., Kaloshi, G., Amiel‐Benouaich, A., Lejeune, J., Marie, Y., Mandonnet, E., Kujas, M., Mokhtari, K., Taillibert, S., Laigle‐Donadey, F., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21125 · Cited by 207 · cited 1×
“In addition, the spontaneous VDE has been shown to reflect the imaging, histopathological, and molecular risk factors for LGGs: LGGs with 1p19q codeletion grow slower and those with p53 overexpression grow faster than those without such abnormalities.(12,16,17) By contrast, IDH1 mutation status has no significant impa…”
BackgroundSelf-citationPrognostic significance of imaging contrast enhancement for WHO grade II gliomas
Pallud, J., Capelle, L., Taillandier, L., Fontaine, D., Mandonnet, E., Guillevin, R., Bauchet, L., Peruzzi, P., Laigle-Donadey, F., Kujas, M., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-066 · Cited by 200 · cited 3×
“Malignant transformation was considered when new contrast enhancement appeared (nodular-like pattern) or progressed if originally present (progressive over time pattern) or when histologically proven.(6) These intervals were censored at the date of last follow-up for survivors.”
BackgroundMethodSelf-citationBauman, G., Lote, K., Larson, D., Stalpers, L., Leighton, C., Fisher, B., Wara, W., Macdonald, D., Stitt, L., & Cairncross, J. G. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00284-9 · Cited by 193
Leu, S., von Felten, S., Frank, S., Vassella, E., Vajtai, I., Taylor, E., Schulz, M., Hutter, G., Hench, J., Schucht, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos317 · Cited by 192
Bauman, G. S., Lote, K., Larson, D., Statpers, L., Leighton, C., Fisher, B., Wara, W., Macdonald, D., Stitt, L., & Cairncross, J. G. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)90145-1 · Cited by 176
Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos331 · Cited by 173 · cited 11×
“By contrast, IDH1 mutation status has no significant impact on spontaneous VDE.(12,17) Because IDH1 mutations occur at an early stage of the development of LGG(9,18) and are not significantly involved in tumor growth,(17) we hypothesized that spontaneous VDE and IDH1 mutation status are independent predictors of outco…”
BackgroundSelf-citationIDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R., Sacchetti, A., Lapre, L., Lamfers, M., Leenstra, S., de Jonge, H., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 141
Pallud, J., Taillandier, L., Capelle, L., Fontaine, D., Peyre, M., Ducray, F., Duffau, H., & Mandonnet, E. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31826213de · Cited by 135 · cited 2×
“The VDE was determined on T2-weighted and fluid attenuated inversion recovery sequences using a methodology detailed elsewhere.(10,14) Tumor volumes were computed on digitized images or calculated using an ellipsoid approximation (volume1⁄4 D1×D2×D3/2) after manual measurements of the 3 largest tumor diameters in 3 or…”
BackgroundMethodSelf-citationMandonnet, E., Pallud, J., Clatz, O., Taillandier, L., Konukoğlu, E., Duffau, H., & Capelle, L. (2008) · Neurosurgical Review · doi:10.1007/s10143-008-0128-6 · Cited by 129 · cited 1×
“The VDE was determined on T2-weighted and fluid attenuated inversion recovery sequences using a methodology detailed elsewhere.(10,14) Tumor volumes were computed on digitized images or calculated using an ellipsoid approximation (volume1⁄4 D1×D2×D3/2) after manual measurements of the 3 largest tumor diameters in 3 or…”
MethodSelf-citationThon, N., Eigenbrod, S., Kreth, S., Lutz, J., Tonn, J., Kretzschmar, H. A., Peraud, A., & Kreth, F.-W. (2011) · Cancer · doi:10.1002/cncr.26298 · Cited by 96
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis
Sun, H., Yin, L.-H., Li, S., Han, S., Song, G., Liu, N., & Yan, C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1107-5 · Cited by 83
Arita, H., Narita, Y., Takami, H., Fukushima, S., Matsushita, Y., Yoshida, A., Miyakita, Y., Ohno, M., Shibui, S., & Ichimura, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1203-9 · Cited by 77
Predictive and prognostic factors for gliomas
Ducray, F., Idbaïh, A., Wang, X.-W., Cheneau, C., Labussière, M., & Sanson, M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.202 · Cited by 73 · cited 1×
“status has been shown to correlate independently with overall survival in gliomas whatever their histopathological grade.(8,9,15) The spontaneous VDE has been shown to correlate independently with malignant progression-free survival and with overall survival.”
BackgroundBlonski, M., Pallud, J., Gozé, C., Mandonnet, E., Rigau, V., Bauchet, L., Fabbro, M., Beauchesne, P. D., Baron, M.-H., Fontaine, D., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1106-6 · Cited by 70 · cited 3×
“7%).(21) The mean tumor spontaneous VDE before first oncological treatment was 5.”
BackgroundSelf-citationPallud, J., Llitjos, J.-F., Dhermain, F., Varlet, P., Dezamis, E., Devaux, B., Souillard-Scemama, R., Sanai, N., Koziak, M., Page, P., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos069 · Cited by 69 · cited 2×
“different series.(12,17,20,21) The mean age at histological diagnosis was 38.”
BackgroundSelf-citationNo prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
Ahmadi, R., Stockhammer, F., Becker, N., Hohlen, K., Misch, M., Christians, A., Dictus, C., Herold‐Mende, C. C., Capper, D., Unterberg, A. W., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0863-y · Cited by 67
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth
Gozé, C., Bezzina, C., Gozé, É., Rigau, V., Maudelondé, T., Bauchet, L., & Duffau, H. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0831-6 · Cited by 49 · cited 6×
“By contrast, IDH1 mutation status has no significant impact on spontaneous VDE.(12,17) Because IDH1 mutations occur at an early stage of the development of LGG(9,18) and are not significantly involved in tumor growth,(17) we hypothesized that spontaneous VDE and IDH1 mutation status are independent predictors of outco…”
BackgroundSelf-citationA population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1)
Dahlrot, R. H., Kristensen, B. W., Hjelmborg, J., Herrstedt, J., & Hansen, S. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1186-3 · Cited by 36
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., Spasojevic, I., Bigner, D. D., He, Y., & Yan, H. (2012) · Oncotarget · doi:10.18632/oncotarget.577 · Cited by 35
Zhu, J., Cui, G., Chen, M., Xu, Q., Wang, X., Zhou, D., Lv, S., Fu, L., Wang, Z., & Zuo, J. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9890-6 · Cited by 23
Berger (1994) · doi:10.1002/1097-0142(19940915)74:6<1784::aid-cncr2820740622>3.0.co;2-d · cited 3×
“The recorded therapeutic characteristics gathered from clinical reports included treatments (surgical resection, chemotherapy, and radiotherapy), extent of resection (biopsy vs partial removal with residual tumor ≥10 cc vs subtotal removal with residual tumor ,10 cc vs total removal with no residual tumor, according t…”
MethodInfluential
Cited by
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 140
Verburg, N., Koopman, T., Yaqub, M. M., Hoekstra, O. S., Lammertsma, A. A., Barkhof, F., Pouwels, P. J. W., Reijneveld, J. C., Heimans, J. J., Rozemuller, A. J. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz180 · Cited by 109
C IC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas
Gleize, V., Alentorn, A., de Kérillis, L. C., Labussière, M., Nadaradjane, A. A., Mundwiller, E., Ottolenghi, C., Mangesius, S., Rahimian, A., Ducray, F., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24443 · Cited by 109
“Finally, we deduced from the volume the mean tumor diameter, a value known to have a linear growth.(21,22) We also showed a significantly faster growth for CIC mutants than for CIC WTs (Fig 2C).”
MethodPrognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Xia, L., Wu, B., Fu, Z., Fěng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4008 · Cited by 86
“Fifty-five studies were included: 9 studies from America, 17 from Asia and 29 from Europe [8–11, 13, 17–66].”
BackgroundSurgery of insular and paralimbic diffuse low-grade gliomas: technical considerations
Michaud, K., & Duffau, H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2120-2 · Cited by 72
Self-citation
Metadata
- Authors
- Goze, C., Blonski, M., Le Maistre, G., Bauchet, L., Dezamis, E., Page, P., Varlet, P., Capelle, L., Devaux, B., Taillandier, L., Duffau, H., & Pallud, J.
- Affiliations
- Inserm (FR)
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-20
- Volume
- 16
- Issue
- 8
- Pages
- 1100-1109
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC4096178
- OpenAlex
- W2111168085
- Cited by
- 56
- References
- 36
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 7 · 2017: 9 · 2016: 4 · 2015: 5 · 2014: 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- diffuse low-grade glioma, IDH1 mutation, tumor growth rate, prognostic factors, malignant transformation, progression-free survival, overall survival, adult glioma
- MeSH terms
- Adult, Aged, Brain Neoplasms, Female, Genetic Testing, Glioma, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Prognosis, Retrospective Studies, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.